Elibol, BülentBora, Ayşe TokcaerSaka, EsenDemirkıran, MeltemAkbostancı, CenkDoğu, OkanÇolakoğlu, BerilKenangil, GülayKaleagası, Hakan2023-01-022023-01-022017-08-12Eryılmaz, I. E. vd. (2017). ''Epigenetic approach to early-onset Parkinson's disease: low methylation status of SNCA and PARK2 promoter regions''. Neurological Research, 39(11), 965-972.0161-6412https://doi.org/10.1080/01616412.2017.1368141https://www.tandfonline.com/doi/full/10.1080/01616412.2017.13681411743-1328http://hdl.handle.net/11452/30224Background and aim: The effect of epigenetic modifications in the genes related to Parkinson's disease (PD) is still unclear. In the present study, we investigated methylation status of SNCA and PARK2 genes in patients with early-onset Parkinson's disease (EOPD). Materials and methods: The promoter region methylation status of SNCA and PARK2 genes was evaluated by methylation specific-PCR (MSP) in 91 patients with EOPD and 52 healthy individuals. Results: The methylation of SNCA and PARK2 promoter regions were significantly lower in EOPD patients compared to the control group (P = 0.013 and P = 0.03, respectively). We also found that the methylation status of the SNCA might be associated with positive family history of PD (P = 0.042). Conclusion: Although it should be supported by further analysis, based on the results of the present study, the methylation status of SNCA and PARK2 genes might contribute to EOPD pathogenesis.eninfo:eu-repo/semantics/closedAccessNeurosciences & neurologyEarly-onset parkinson’s diseaseEpigeneticMethylationPARK2SNCAAlpha-synucleinLeukocyte dnaGeneMutationsExpressionAge of onsetalpha-synucleinCpG islandsEpigenesis, geneticFemaleGenetic predisposition to diseaseHumansMaleMiddle agedParkinson diseasePedigreePromoter regionsGeneticUbiquitin-protein ligasesDNA methylationArticle0004140529000042-s2.0-85028553453965972391128830306Clinical neurologyNeurosciencesPTEN-induced Putative Kinase; Parkin Protein; Protein Deglycase DJ-1Alpha synucleinBisulfiteLevodopaParkin 2Ubiquitin protein ligase E3Unclassified drugAlpha synucleinParkinSNCA protein, humanUbiquitin protein ligaseAdultArticleControlled studyCpG islandDisease durationDNA methylationDNA sequenceEpigeneticsExonFemaleGeneGenetic associationHumanMajor clinical studyMaleMiddle agedMissense mutationNonsense mutationPARK2 geneParkinson diseasePolymerase chain reactionPromoter regionSNCA geneUnified parkinson disease rating scaleGenetic epigenesisGenetic predispositionGeneticsMetabolismOnset ageParkinson diseasePedigree